Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NIS793 |
Synonyms | |
Therapy Description |
NIS793 is a monoclonal anti-transforming growth factor beta (TGF-beta) antibody that blocks TGF-beta signaling, leading to tumor growth inhibition (PMID: 31692434). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NIS793 | nisevokitug | TGFB (Pan) Antibody 5 | NIS793 is a monoclonal anti-transforming growth factor beta (TGF-beta) antibody that blocks TGF-beta signaling, leading to tumor growth inhibition (PMID: 31692434). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02947165 | Phase I | NIS793 + Spartalizumab NIS793 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | Completed | USA | ITA | DEU | CHE | CAN | AUT | 3 |
NCT04810611 | Phase I | NIS793 Sabatolimab Canakinumab + Sabatolimab NIS793 + Sabatolimab Canakinumab | Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS | Terminated | USA | ITA | ISR | ESP | AUS | 2 |